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CHMP4B, a Novel Gene for Autosomal Dominant Cataracts Linked
to Chromosome 20q
Alan Shiels, Thomas M. Bennett, Harry L. S. Knopf, Koki Yamada, Koh-ichiro Yoshiura,
Norio Niikawa, Soomin Shim, and Phyllis I. Hanson
Cataracts are a clinically diverse and genetically heterogeneous disorder of the crystalline lens and a leading cause of
visual impairment. Here we report linkage of autosomal dominant “progressive childhood posterior subcapsular” cataracts
segregating in a white family to short tandem repeat (STR) markersD20S847 (LOD score [Z] 5.50 at recombination fraction
[v] 0.0) and D20S195 ( at ) on 20q, and identify a reﬁned disease interval (rs2057262–(3.8Mb)–rs1291139)Zp 3.65 vp 0.0
by use of single-nucleotide polymorphism (SNP) markers. Mutation proﬁling of positional-candidate genes detected a
heterozygous transversion (c.386ArT) in exon 3 of the gene for chromatin modifying protein-4B (CHMP4B) that was
predicted to result in the nonconservative substitution of a valine residue for a phylogenetically conserved aspartic acid
residue at codon 129 (p.D129V). In addition, we have detected a heterozygous transition (c.481GrA) in exon 3 ofCHMP4B
cosegregating with autosomal dominant posterior polar cataracts in a Japanese family that was predicted to result in the
missense substitution of lysine for a conserved glutamic acid residue at codon 161 (p.E161K). Transfection studies of
cultured cells revealed that a truncated form of recombinant D129V-CHMP4B had a different subcellular distribution
than wild type and an increased capacity to inhibit release of virus-like particles from the cell surface, consistent with
deleterious gain-of-function effects. These data provide the ﬁrst evidence that CHMP4B, which encodes a key component
of the endosome sorting complex required for the transport-III (ESCRT-III) system of mammalian cells, plays a vital role
in the maintenance of lens transparency.
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Hereditary forms of cataracts are usually diagnosed at
birth (congenital), during infancy, or during childhood
and are clinically important as a cause of impaired form
vision development.1 In addition to being found in 150
genetic syndromes involving other ocular defects (e.g.,mi-
crophthalmia [MIM 212550]) and systemic abnormalities
(e.g., galactokinase deﬁciency [MIM 230200]), cataracts
may be inherited as an isolated lens phenotype, most
frequently by autosomal dominant transmission.2 So far,
genetic linkage studies of 160 families worldwide have
mapped at least 25 independent loci for clinically diverse
forms of nonsyndromic cataracts on 15 human chromo-
somes, involving some 17 lens-abundant genes.2 The
majority of associated mutations have been identiﬁed in
10 crystallin genes (CRYAA [MIM 123580], CRYAB [MIM
123590], CRYBB1 [MIM 600929], CRYBB2 [MIM 123620],
CRYBB3 [MIM 123630], CRYBA1 [MIM 123610], CRYBA4
[MIM 123631], CRYGC [MIM 123680], CRYGD [MIM
123690], and CRYGS [MIM 123730]),3–11 which encode the
major “refractive” proteins of the lens. The remainingmu-
tations have been identiﬁed in seven functionally diverse
genes, including those coding for gap-junction connexin
proteins (GJA3 [MIM 121015], GJA8 [MIM 600897]),12,13
a heat-shock transcription factor (HSF4 [MIM 602438]),14
an aquaporin water channel (MIP [MIM 154050])15 a clau-
din-like cell-junction protein (LIM2 [MIM 154045]),16 and
intermediate-ﬁlament-like cytoskeletal proteins (BFSP1
[MIM 603307], BFSP2 [MIM 603212]).17,18 In addition to
the known genes, at least 10 novel genes for autosomal
dominant or recessive forms of nonsyndromic cataracts
remain to be identiﬁed at loci on chromosomes 1 (CCV
[MIM 115665], CTPP1 [MIM 116600]), 2 (PCC [MIM
601286], CCNP [MIM 607304, MIM 115800]), 3 (CATC2
[MIM 610019]), 9 (CAAR [MIM 605749]), 15 (CCSSO
[MIM 605728]), 17 (CTAA2 [MIM 601202], CCA1 [MIM
115660]), 19 (CATCN1 [MIM 609376]), and 20 (CPP3
[MIM 605387]).19–32 Here we have ﬁne-mapped a locus for
autosomal dominant cataracts on chromosome 20q and,
subsequently, have identiﬁed underlying missense muta-
tions in the gene for chromatin modifying protein-4B
(CHMP4B [MIM 610897]), also known as charged multi-
vesicular body protein-4B, which has not previously been
associated with human disease.
Linkage studies.—We investigated a six-generationwhite
family from the United States (family Sk) segregating au-
tosomal dominant progressive childhood posterior sub-
capsular cataracts (PCPSC) in the absence of other ocular
or systemic abnormalities (ﬁg. 1A). Ophthalmic records
indicated that the cataracts presented in both eyes as disc-
shaped posterior subcapsular opacities, progressing with
age to affect the nucleus and anterior subcapsular regions
of the lens (ﬁg. 1B). The age at diagnosis varied from 4 to
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20 years, and the age at surgery ranged from 4 to 40 years.
Postsurgical corrected visual acuity varied from 20/20 to
20/200 in the better eye. Blood samples were obtained
from 27 family members, and leukocyte genomic DNA
was puriﬁed and quantiﬁed using standard techniques
(Qiagen). Ethical approval for this study was obtained
from the Washington University Human Research Protec-
tion Ofﬁce, and written informed consent was provided
by all participants prior to enrollment, in accordance with
the tenets of the Declaration of Helsinki.
For linkage analysis, 15 affected individuals, 8 unaf-
fected individuals, and 4 spouses from family Sk were ge-
notyped using STRmarkers from the combinedGe´ne´thon,
Marshﬁeld, and deCODE genetic linkage maps (National
Center for Biotechnology Information [NCBI]), as de-
scribed elsewhere.33 Following exclusion of linkage to
known loci for autosomal dominant cataracts on chro-
mosomes 1–3, 10–13, 15–17, 19, 21, and 22 (table 1), we
obtained signiﬁcant evidence of linkage (table 2) formark-
ers D20S847 ( and ), D20S195 ( andZp 5.50 vp 0 Zp 3.65
), and D20S870 ( and ).vp 0 Zp 3.11 vp 0
Haplotype analysis detected seven recombinant indi-
viduals within the Sk pedigree (ﬁg. 1A). First, two affected
females, VI:4 and VI:6, were obligate recombinants, prox-
imally at D20S885 and distally at D20S855, respectively.
Second, three affected females (IV:1, IV:4, and V:3) and
one affected male (VI:1) were obligate recombinants dis-
tally at D20S834. Third, one affected female (V:3) and her
affected son (VI:1) were obligate recombinants proximally
at D20S837. However, with the exception of individual V:
5 (see below), no further recombinant individuals were
detected at four other intervening STR markers, suggest-
ing that the cataract locus lay in the physical interval,
D20S837–(4.7 Mb)–D20S834.
At the time of our study, individual V:5 was 17 years of
age and phenotypically unaffected; however, he inherited
the complete disease haplotype (ﬁg. 1A), suggesting that
he was either nonpenetrant or presymptomatic for cata-
racts. The two-point LOD scores shown in table 2 were
calculated with the assumption of unaffected status for
individual V:5 and 95% penetrance in family Sk; however,
even when 100% penetrance was assumed, we still re-
tained signiﬁcant evidence of linkage proximally at
D20S195 ( at ) and distally atZ p 4.31 v p 0.04max max
D20S847 ( at ). Conversely, if in-Z p 5.08 v p 0.04max max
dividual V:5 developed cataracts later in life, perhaps ex-
tending the age-at-onset range in family Sk, and was in-
cluded with the assumption of preaffected status and
100% penetrance, we would obtain enhanced evidence
for linkage (D20S195, at ; D20S847,Z p 5.12 v p 0.0max max
at ). However, regardless of whetherZ p 6.97 v p 0.0max max
individual V:5 was included or excluded, we found no
evidence of linkage at other candidate genes or loci for
autosomal dominant cataracts (table 1).
To further reﬁne the disease interval, we genotyped fam-
ily Sk with biallelic SNP markers (NCBI) located within
the STR interval using conventional dye-terminator cycle-
sequencing chemistry (Applied Biosystems). Critical af-
fected individuals IV:1, IV:4, and V:3 were also found to
be recombinant at SNP marker rs1291139 (A/T), which lies
∼0.5 Mb centromeric to D20S834. Similarly, critical af-
fected individuals V:3, and VI:1 were also recombinant at
marker rs2057262 (A/C) located ∼0.4 Mb telomeric to
D20S837 (ﬁg. 1A). However, individual V:5 excepted, no
further recombination events were detected at intervening
SNP markers, indicating that the cataract locus lay in the
reduced (∼0.9 Mb) physical interval, rs2057262–(3.8Mb)–
rs1291139 (ﬁg. 1C).
Mutation analysis.—The reﬁned SNP interval contained
∼80 positional-candidate genes, none of which were ob-
vious functional candidates for cataracts in family Sk
(NCBI Map Viewer). We prioritized genes for mutation
analysis of exons and intron boundaries (splice sites) on
the basis of three main criteria.
1. NCBI reference sequence status, with those genes des-
ignated “reviewed” or “provisional” selected over
those designated “model” or “pseudogene.”
2. Evidence of expression in (fetal) eye, from the
UniGene EST database.
3. Number of exons or amplicons required for coverage
of the coding region, starting with smaller genes ﬁrst.
Resequencing analysis of individuals IV:5, V:6, V:10, and
VI:6 from the Sk pedigree (ﬁg. 1A) excluded the presence
of coding or splice-site mutations in eight genes (data
not shown), including EPB41L1 (MIM 602879), E2F1
(MIM 189971), ZNF341, PXMP4, ITGB4BP (MIM 602912),
APBA2BP, SCAND1 (MIM 610416), and DYNLRB1 (MIM
607167). However, resequencing of a 5-exon gene sym-
bolized CHMP4B (GeneID: 128866) identiﬁed a hetero-
zygous c.386ArT transversion in exon 3 that was not pre-
sent in wild type (ﬁg. 2B). This single-nucleotide change
did not result in the gain or loss of a convenient restriction
site; therefore, we designed allele-speciﬁc (A/T) PCR anal-
ysis to conﬁrm that the mutant “T” allele cosegregated
with affected but not unaffected members of family Sk,
with the exception of individual V:5 (ﬁg. 2C). Further-
more, when we tested the c.386ArT transversion as a bial-
lelic marker, with a notional allelic frequency of 1%, in a
two-point LOD score analysis of the cataract locus (table
2) we obtained further compelling evidence of linkage
( at ). In addition, we conﬁrmed that theZp 6.52 vp 0
c.386ArT transversion was not listed in the NCBI SNP
database (dbSNP), and we excluded it as a SNP in a panel
of 192 normal, unrelated individuals (i.e., 384 chromo-
somes), using the allele-speciﬁc PCR analysis described in
ﬁg. 2C (data not shown). Although it is possible that an
undetected mutation lay elsewhere within the disease-
haplotype interval (3.8 Mb), our genotype data strongly
suggested that the c.386ArT transversion in exon 3 of
CHMP4B represented a causative mutation rather than a
benign SNP in linkage disequilibrium with the cataract
phenotype.
To verify that the c.386ArT transversion in CHMP4B
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Figure 1. Autosomal dominant PCPSC in a six-generation family (Sk). A, Pedigree and haplotype analysis showing segregation of
eight STR markers and two SNP markers on 20q, listed in descending order from the centromere. Squares and circles denote males and
females, respectively. Filled symbols and bars denote affected status and haplotypes, respectively. Individual V:5 is marked with a
question mark (?) to denote unknown status. Pedigree and haplotype data were managed using Cyrillic 2.1 software (FamilyGenetix).
B, Slit-lamp image of lens from affected female V:12 (age 40 years) showing posterior subcapsular, nuclear, and anterior subcapsular
opacities. C, Ideogram of chromosome 20, comparing the cytogenetic location of SNP markers deﬁning the PCPSC locus in this study
(red) with those of STR markers deﬁning loci for CPP3 and PCZNC.31,32
was present at the RNA transcript level in family Sk, we
performed allele-speciﬁc RT-PCR analysis of peripheral
blood leukocytes (PBLs), which have been shown to ex-
press CHMP4B.35 PCR primers (table 3) were designed to
amplify the entire coding region of CHMP4B (codons 1–
224) in the presence of a nested mutant (T allele) primer
to detect heterozygosity in three consenting relatives, in-
cluding individual V:5 (ﬁg. 3A). The affected father (IV:5)
and his son (V:5) were heterozygous for the wild-type (A
allele) and mutant (T allele) transcripts, whereas his un-
affected daughter (V:6) was homozygous for the wild-type
(A allele) transcript. To gain a more accurate comparison
of wild-type versus mutant CHMP4B transcript levels in
PBL RNA, we then performed quantitative (q)RT-PCRwith
SYBR Green-1 in real time (ﬁg. 3B), using a sense anchor
primer paired with either a mutant (T allele) or wild-type
(A allele) primer (table 3).When standardized against tran-
script levels for the midabundance ribosomal protein-L19
(RPL19), the ratio of wild-type to mutant CHMP4B tran-
scripts was estimated to be 60(A):40(T), suggesting de-
creased expression and/or increased turnover of the
mutant transcript in affected individuals. Overall, the
transcript and genotype data are consistent for these in-
dividuals (ﬁg. 1A and ﬁg. 3A) and support the view that
the clinically unaffected son (V:5) is either presymptom-
atic or nonpenetrant for the cataract phenotype. More-
over, the ability to amplify the intact coding region of
CHMP4B transcripts from affected individuals was con-
sistent with correct mRNA splicing, suggesting that the
c.386ArT transversion, which is located near the begin-
ning of exon 3, did not activate a cryptic splice site.36
Finally, we also conﬁrmed that the intact coding region
of CHMP4B transcripts could be ampliﬁed from human
and mouse post mortem lenses (ﬁg. 3C), consistent with
a functional role for CHMP4B in lens biology.
CHMP4B is cytogenetically distinct from BFSP1 and an
interval on 20p (ﬁg. 1C) that was linked recently with
autosomal dominant progressive congenital zonular nu-
clear cataract (PCZNC) segregating in a Chinese family.32
However, CHMP4B is located within a much larger region
spanning 20p12–20q12 that was previously linked with
autosomal dominant posterior polar cataract (CPP3 [MIM
605387]) segregating in a Japanese family.31 Like the cat-
aracts in family Sk, CPP3 was characterized by a juvenile
onset and progressive disc-shaped posterior subcapsular
opacities along with some cortical opaciﬁcation.37 To in-
vestigate the possibility of allelism, we performed a similar
mutation screen of CHMP4B in the CPP3 family and iden-
tiﬁed a heterozygous c.481GrA transition in exon 3 that
was not present in wild type (ﬁg. 4A and 4B) or in the
SNP database. This single-nucleotide change removed an
adjacentMnl1 restriction enzyme-site, and restriction frag-
ment length analysis conﬁrmed that the heterozygous A
allele cosegregated with affected members of the CPP3
family but was not present in unaffected relatives or our
control panel (ﬁg. 4C and data not shown). The identi-
ﬁcation of a second coding nucleotide change in a geo-
graphically and ethnically distinct family provided strong
supporting evidence for CHMP4B as the causative gene for
cataracts linked to 20q. In addition, the locus for lens
opacity-4 (Lop4)38 has been linked to a region of murine
chromosome 2 that is syntenic with human 20q11.2 rais-
ing the possibility of a mouse model for the cataracts de-
scribed here.
CHMP4B encodes a highly charged helical protein (∼25
kDa) with N-terminal basic and C-terminal acidic halves
(ﬁg. 5B). The c.386ArT transversion in exon 3 occurred
at the second base of codon 129 (GATrGTT), and is pre-
dicted to result in the missense substitution of aspartic
acid to valine (p.D129V) at the level of translation. Sim-
ilarly, the c.481GrA transition occurred at the ﬁrst base
of codon 161 (GAGrAAG) of exon 3, and is predicted to
translate as a missense substitution of glutamic acid to
lysine (p.E161K). Cross-species alignment of the amino
acid sequences for CHMP4B present in the Entrez Pro-
tein database, performed by means of ClustalW, revealed
that p.D129 and p.E161 are phylogenetically conserved
from yeast to man (ﬁg. 5C). Moreover, the predicted
p.D129V and p.E161K substitutions represented noncon-
servative amino acid changes, with the acidic side-group
(CH2COOH) of aspartic acid replaced by the neutral, hy-
drophobic side-group (CHC2H6) of valine, and the
acidic side-group (C2H4COOH) of glutamic acid replaced
by the basic side-group (C4H8NH2) of lysine, respectively,
suggestive of functional consequences.
Functional expression studies.—Eleven CHMP genes have
been identiﬁed in the human genome and, on the basis
of phylogenetic analyses, have been divided into seven
subfamilies, some with multiple members.39,40 CHMP4B is
one of three human orthologs of yeast Snf7/Vps32 (su-
crose non-fermenting-7 or vacuolar protein sorting-32),
which functions in protein sorting and transport in the
endosome-lysosome pathway.39 In the current model,
CHMP4B is a core subunit of the endosomal-sorting com-
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Table 1. Two-point LOD scores (Z) Showing Exclusion of
Linkage between the Autosomal Dominant Cataract Locus
and STR Markers near Candidate Genes or Loci on
Chromosomes Other Than 20
Marker Za v Chromosome Gene/Locus
D1S243 2.77 .10 1p36 CCV, CPP1
D1S214 2.93 .10
D1S2748 2.14 .20 1p32 FOXE3[MIM 601094]
D1S305 2.01 .20 1q21 GJA8
D2S2333 2.35 .20 2p12 CCNP
D2S128 3.19 .05 2q32-q36 CRYGC, CRYGD, CRYBA2
D2S2248 2.75 .20
D3S1768  .00 3p21.1-p21.3 CATC2
D3S3564 2.34 .05
D3S1292 1.76 .05 3q22.1 BFSP2
D3S3686 4.04 .10 3q27.2 CRYGS
D5S2014 2.05 .05 5q33.1 SPARC [MIM 182120]
D6S1710 2.37 .05 6q12 GLULD1
D9S303 1.31 .05 9q21.31 CAAR
D9S1120 1.28 .05
D10S566 2.94 .10 10q24-q25 PITX3[MIM 602669]
D10S1697 3.01 .10
D11S4154 2.63 .05 11p13 PAX6 [MIM 607108]
D11S4192 2.55 .10 11q23.1 CRYAB
D11S1347 3.28 .05
D12S368 1.94 .10 12q13.3 MIP
D13S175 2.34 .05 13q11 GJA3
D14S1047 2.12 .05 14q24.3 CHX10[MIM 142993]
D15S209 3.14 .05 15q21-q22 CCSSO
D15S1036 2.41 .20
D16S412 2.51 .10 16p12.3 CRYM[MIM 123740]
D16S3095 2.99 .10 16q22.1 HSF4
D17S1840 2.45 .05 17p13 CTAA2
D17S796 2.13 .10
D17S799 1.79 .05 17q11.2 CRYBA1
D17S798 1.18 .05
D17S785 2.14 .10 17q24 GALK1[MIM 604313]
D17S802 1.91 .05 17q24 CCA1
D17S784 2.67 .10
D19S412 2.41 .15 19q13 LIM2
D20S112 2.58 .08 20p11.23 BFSP1
D20S885 2.71 .10 20p12–20q12 CPP3
D20S847 5.08 .04
D21S1259 2.78 .10 21q22.3 CRYAA
D21S1885 .81 .00
D22S1154 2.20 .15 22q11.23-q21.1 CRYBA4, CRYBB1-4
a A gene frequency of 0.0001 and a penetrance of 100% were assumed
for the disease locus.
Figure 2. Mutation analysis of CHMP4B in family Sk. A, Sequence
trace of the wild-type allele, showing translation of aspartic-acid
(D) at codon 129 (GAT). B, Sequence trace of the mutant allele,
showing the heterozygous c.386ArT transversion (denoted as W
by the International Union of Pure and Applied Chemistry [IUPAC]
code) that is predicted to result in the missense substitution of
valine (GTT) for aspartate at codon 129 (p.D129V). Exons and
ﬂanking intron regions were ampliﬁed with gene-speciﬁc primers
(M13-tailed) by use of the AmpliTaq PCR Master Mix in a GeneAmp
9700 thermal-cycler (Applied Biosystems). Resulting amplicons
were puriﬁed using the QIAquick gel-extraction kit (Qiagen) and
then direct sequenced in both directions with M13-primers and
the BigDye Terminator (v.3.1) cycle sequencing kit on a 3130xl
genetic analyzer running SeqScape mutation-proﬁling software
(Applied Biosystems). C, Allele-speciﬁc PCR analysis using the
three primers (table 3) indicated by arrows in the schematic di-
agram; exon 3 was ampliﬁed as above with the sense (anchor)
primer located in intron 2 (Ex3F), the anti-sense primer located
in intron 3 (Ex3R), and the nested mutant primer speciﬁc for the
T allele in codon 129 (T-alleleR). PCR products were visualized
(302 nm) on 2% agarose gels stained with ethidium bromide
(EtBr). Note that only affected members of family Sk are hetero-
zygous for the T allele (171 bp), with the exception of individual
V:5, who is believed to be presymptomatic or nonpenetrant for
cataracts.
plex required for transport-III (ESCRT-III), which facilitates
the biogenesis of multivesicular bodies (MVBs).39 The only
CHMP gene so far implicated in human disease isCHMP2B
(yeast ortholog Vps2/Did4 [MIM 609512]), which has
been reported to harbormutations infrequently associated
with frontotemporal dementia (FTD [MIM 600795]) and
amyotropic lateral sclerosis (ALS [MIM 609512]).41–43
CHMP4B is found diffusely throughout the cytoplasm
and/or in association with endosome-like compartments
when expressed in cultured mammalian cells.44,45 To de-
termine the effect of the p.D129V substitution on the sub-
cellular distribution of CHMP4B, we transfected African
green monkey kidney (COS-7) cells with expression plas-
mids46 encoding either wild-type or mutant forms of
CHMP4B tagged at the N-terminus with the FLAG epitope.
Immunoﬂuorescence microscopy with FLAG antibody re-
vealed that full-length wild-type (FLAG-CHMP4B) and
mutant protein (FLAG-D129V-CHMP4B) were diffusely
distributed (ﬁg. 6A and 6B). At higher expression levels,
both were associated with endosome-like compartments
(data not shown). Overall, there were no notable differ-
ences in the subcellular localization of wild type and
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Table 2. Two-Point LOD Scores (Z) for Linkage between the Cataract Locus and




from p-tel Za at v p
Zmax vmaxcM Mb .00 .05 .10 .20 .30 .40
D20S885 39.9 17.91 7.79 2.51 2.72 2.35 1.60 .74 2.72 .10
D20S111 49.2 29.94 2.82 1.14 1.17 .91 .54 .19 1.18 .08
D20S837 50.7 30.73 .81 4.15 3.98 3.18 2.14 1.01 4.15 .05
rs2057262 31.15 4.03 .02 .14 .16 .09 .03 .17 .15
D20S195 50.2 31.29 3.65 4.17 3.88 2.96 1.90 .87 4.20 .03
CHMP4B
(A1T)
31.90 6.24 5.87 5.37 4.19 2.82 1.36 6.24 .00
D20S909 50.7 33.92 1.89 1.88 1.72 1.25 .73 .33 1.91 .02
D20S896 50.2 34.16 2.88 2.60 2.30 1.68 1.05 .46 2.88 .00
D20S870 50.7 34.16 3.11 2.93 2.63 1.94 1.23 .59 3.11 .00
D20S847 50.2 34.32 5.50 5.18 4.72 3.60 2.33 1.05 5.50 .00
rs1291139 34.95 1.85 .99 1.10 .96 .66 .30 1.10 .11
D20S834 50.7 35.43 1.08 2.07 1.91 1.30 .65 .19 2.07 .05
D20S607 54.9 38.23 1.61 1.85 2.02 1.81 1.30 .66 2.03 .11
D20S855 56.0 39.08 .29 3.26 3.19 2.58 1.71 .77 3.27 .06
NOTE.—STR marker allele frequencies used for linkage analysis were those calculated by Ge´ne´-
thon/Marshﬁeld/deCODE. A gene frequency of .0001 and a penetrance of 95% were assumed for
the disease locus.
a Z values were calculated using the MLINK subprogram from the LINKAGE (5.1) package of
programs.34
Table 3. PCR Primers for Mutation Screening and
Transcript Analysis of CHMP4B
Primer Location Strand Sequence (5′r3′)a
Ex1F Exon 1 Sense gtagtcagtggcgcgttg
Ex1R Intron 1 Antisense aggcgagtctgatgaaggtg
Ex2F Intron 1 Sense cactagaacctcaccctgtgc
Ex2R Intron 2 Antisense aaacaaactcaggtgctcgaa
Ex3F Intron 2 Sense tcacagggagtcattgcaggg
Ex3R Intron 3 Antisense cccaccctggaaaggtgcag
Ex3R2 Intron 3 Antisense agggacagcctcagggtatcattt
Ex4F Intron 3 Sense cacagggtctggaacctggaa
Ex4R Intron 4 Antisense tgggcaagctcaggacacaga
Ex5F1 Intron 4 Sense aacatgttgaacgcaccagtc
Ex5R1 Exon 5 Antisense AGGTCATTTCAACTGCAACCA
Ex5F2 Exon 5 Sense CGCTGACTCCACTGCTGAATCC
Ex5R2 Exon 5 Antisense ctggaaagggtcagctcccg
StartF Exon 1 Sense caccATGTCGGTGTTCGGGAAGCT
EndR Exon 5 Antisense CATGGATCCAGCCCAGTTCTCCAA
A-alleleR Exon 3 Antisense CAGCAATGTCCTGCATTAACTCAT
T-alleleR Exon 3 Antisense CAGCAATGTCCTGCATTAACTCAA
a Noncoding sequence is shown in lowercase, coding sequence
in uppercase.
p.D129V mutant protein. In contrast, similar expression
studies of a splicingmutation inCHMP2B underlying FTD,
which resulted in truncation (36 amino acids) and mis-
coding (29 amino acids) at the C-terminus of the full-
length protein (residues 1–213), has been associated with
redistribution of CHMP2B and the formation of dys-
morphic organelles of the late endosomal pathway.41
The p.D129V missense substitution was predicted to be
located centrally in CHMP4B and to result in the net loss
of a negatively charged residue (ﬁg. 5B). Domain expres-
sion studies have revealed that the N-terminal half of
CHMP4A (MIM 610051), an isoform of CHMP4B, is re-
sponsible for self-association into polymers and binding
to membrane phospholipids.46 To better appreciate the ef-
fects of the p.D129V substitution, we compared the sub-
cellular localization of wild-type and mutant N-terminal
fragments of CHMP4B (residues 1–150) comparable to
those previously studied.46,47 As expected, the distribution
of the truncated wild-type fragment (FLAG-CHMP4B1–150)
differed from that of the full-length wild-type protein; the
former appeared to be in large polymers and sometimes
associated with vacuolar structures (ﬁg. 6C), whereas the
latter was diffuse (ﬁg. 6A). Similarly, the truncatedmutant
fragment (FLAG-D129V-CHMP4B1–150) differed from the
full-length mutant protein; the former was concentrated
on a punctate perinuclear structure (ﬁg. 6D), and the latter
was again diffuse (ﬁg. 6B). Consistently, however, the trun-
cated mutant fragment (ﬁg. 6D) displayed a different sub-
cellular distribution pattern from that of the truncated
wild-type fragment (ﬁg. 6C).
In addition to MVB formation, CHMP4B is thought to
participate in the budding of a number of RNA viruses,
including human immunodeﬁciency virus type-1 (HIV-1),
from the surface of infected cells.45 To further investigate
the effect of the p.D129V substitution on CHMP4B activ-
ity in a functional assay, we compared the effect of ex-
pressing wild-type and mutant protein on release of HIV-
1 virus-like-particles (VLPs). To monitor VLP production,
human embryonic kidney (HEK 293T) cells were cotrans-
fected with a plasmid encoding the HIV-1Gag polyprotein
(Pr55) and a plasmid encoding wild-type or mutant
CHMP4B. HIV-1 Gag forms VLPs in the absence of other
viral proteins,48 and expression of Gag and CHMP4B
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Figure 3. RT-PCR analysis of CHMP4B transcripts in peripheral
blood leukocytes (PBLs) and eye lens. A, Agarose-gel electropho-
resis showing nested ampliﬁcation products of CHMP4B transcripts
in PBL RNA from family Sk, conﬁrming that individuals IV:5 and
V:5 are heterozygous for the mutant T allele (413 bp), whereas
individual V:6 is homozygous for the wild-type A allele (676 bp).
PBL RNA was puriﬁed using the Versagene kit (Gentra), reverse
transcribed with the iScript cDNA synthesis kit (Bio-Rad), and PCR
ampliﬁed as above with three primers (StartF, nested T-alleleR,
and EndR) (table 3). B, Quantitative ampliﬁcation of CHMP4B tran-
scripts from PBL RNA with allele-speciﬁc primers (StartF  A-
alleleR, or StartF  T-alleleR) (table 3) showing the relative levels
of wild-type (A allele) and mutant (T allele) transcripts in indi-
viduals IV:5, V:5, and V:6 from family Sk. RT-PCR products were
ampliﬁed in a 10-fold dilution series (in triplicate) by use of the
iQ SYBR Green Supermix in an iCycler ﬁtted with a MyiQ single-
color real-time PCR detection system (Bio-Rad). Allele-speciﬁc
CHMP4B transcripts were detected by melt-curve analysis and stan-
dardization against control RPL19 transcript, which was ampliﬁed
separately in a similar 10-fold dilution series of the same PBL RT-
PCR products by use of RPL19 forward (5′-catccgcaagcctgtgac-3′)
and reverse (5′-gtgaccttctctggcattcg-3′) primers. C, Agarose-gel
electrophoresis showing amplicons containing the entire coding
region (codons 1–224) of CHMP4B transcripts (676 bp) from human
(Hs) lens (∼30 years old), mouse (Mm) lens (postnatal day 6),
and HEK 293 cells. Post mortem human lenses were obtained from
the Lions Eye Bank of Oregon, and RNA was extracted using TRIzol
reagent (Invitrogen). Following euthanasia (CO2 gas), mouse
lenses were dissected into RNAlater tissue preservative, and RNA
was extracted using the RNAqueous kit (Ambion). RNA was ex-
tracted from cultured HEK 293 cells as for mouse lenses. RT-PCR
of lens and HEK 293 RNA was performed as for PBL RNA above,
with use of StartF and EndR primers (table 3), and the resulting
amplicons were veriﬁed by sequencing.
Figure 4. Mutation analysis of CHMP4B in the CPP3 family. A,
Sequence trace of the wild-type allele showing translation of glu-
tamic-acid (E) at codon 161 (GAG). B, Sequence trace of the mutant
allele showing the heterozygous c.481GrA transition (denoted R
by the IUPAC code) that is predicted to result in the missense
substitution of lysine (AAG) for glutamate at codon 161 (p.E161K).
C, Restriction-fragment–length analysis showing loss of an Mnl1
site (3′-GGAGN6) that cosegregates only with affected individuals
from the Japanese family31 heterozygous for the c.481GrA trans-
version (103 bp). Exon 3 was ampliﬁed with PCR primers (table
3) shown in the schematic diagram and resulting amplicons (326
bp) digested (at 37C for 1 h) with Mnl1 (5 U; New England
BioLabs). Restriction fragments (175 bp) were visualized on 2%
agarose-EtBr gels.
within cells and release of Gag into the media as VLPs was
detected by immunoblotting (ﬁg. 6E). As expected on the
basis of previous results,49 expression of the truncated
wild-type fragment (FLAG-CHMP4B1–150) inhibited VLP re-
lease. Interestingly, the truncatedmutant fragment (FLAG-
D129V-CHMP4B1–150) was a more potent inhibitor than
truncated wild type allowing release of only 53%  7%
(average  SD) as much Gag in VLPs. Correspondingly,
the level of Gag expression in cells expressing the mutant
fragment was 1.4  0.3 times that of cells expressing the
wild-type fragment. In contrast, neither the wild type nor
the mutant forms of full-length CHMP4B signiﬁcantly in-
hibited Gag production or VLP release (data not shown).
Precisely how the p.D129V substitution affects the func-
tion of CHMP4B is unclear. In this study, we found that
the p.D129V substitution changed the subcellular distri-
bution and effects of CHMP4B on VLP release when the
protein’s acidic C-terminus was removed. Previous studies
suggest that the acidic C-termini of CHMPs are regulatory
domains that interact speciﬁcally with their cognate N-
terminal basic domains in an auto-inhibitory manner.46,
49,50 Thus, it is possible that when CHMP4B is relieved
from auto-inhibition (mimicked here by truncation), the
p.D129V substitution is exposed resulting in deleterious
gain-of-function effects. On the basis of expression anal-
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Figure 5. Gene structure and protein domains of CHMP4B. A, Exon organization and mutation proﬁle of CHMP4B. Intron sizes are
indicated (kb), and codons are numbered above each exon. B, Amino acid sequence of CHMP4B, showing the conserved SNF7 domain
(underlined) of this protein family (Conserved Domain Databse, pfam03357) containing at least four predicted helical domains (grey).
The proposed p.D129V and p.E161K substitutions are predicted to be located in the C-terminal acidic half of the protein, near the start
of adjacent helices within the SNF7 domain. Charged amino acids (, ) and the translation stop codon (*) are also indicated. C,
Amino acid sequence alignment of human CHMP4B and orthologs from other species, showing phylogenetic conservation of D129 and
E161.
ysis of the N-terminal region of CHMP4A,46 we speculate
that, once unmasked, the p.D129V substitution alters
the polymerization and/or membrane-binding properties
of CHMP4B; however, other mechanisms cannot be
excluded. Further work will be required to understand
how the p.D129V change affects the behavior of intact
CHMP4B. Functional expression studies are also under-
way to determine how the p.E161K substitution affects
CHMP4B. Although little is known about the role of
CHMP proteins in lens development, endosome-like
compartments have been observed in the newborn
mouse lens.51 Further characterization of endosomal path-
ways in the lens should provide insight into the patho-
genetic mechanisms linking CHMP4B dysfunction with
cataractogenesis.
In conclusion, our data identify the ﬁrst mutations
(p.D129V, p.E161K) in a novel gene (CHMP4B) for inher-
ited cataracts linked to 20q, and they suggest that gain-
of-function defects in an endosome-sorting complex
(ESCRT-III) subunit triggers loss of lens transparency.
Figure 6. Transient expression of CHMP4B in cultured cells. A–D, Subcellular localization of CHMP4B proteins in COS-7 cells, visualized
by immunostaining with FLAG antibody and epiﬂuorescence microscopy. A, Full-length wild-type FLAG-CHMP4B. B, Full-length mutant
FLAG-D129V-CHMP4B. C, Truncated wild-type FLAG-CHMP4B1–150. D, Truncated mutant FLAG-D129V-CHMP4B1–150. For full-length constructs,
the coding sequence (codons 1–224) of human CHMP4B was PCR ampliﬁed from HeLa cDNA (Clontech) with forward (5′-gtagatctatgtcggtgt-
tcgggaagctgttcgg-3′) and reverse (5′-cactcgagttacatggatccagcccagttctcc-3′) primers and then subcloned into the BamHI and XhoI re-
striction sites in the poly-linker of pcDNA3.1-FLAG.46 The D129V substitution was generated using the QuickChange mutagenesis kit
(Stratagene). For truncated CHMP4B constructs, amplicons corresponding to codons 1–150 were ampliﬁed using the full-length constructs
as templates and were subcloned into pcDNA3.1-FLAG as above. Plasmid DNA was prepared using the QIAprep spin kit (Qiagen), and
inserts were veriﬁed by sequencing using the T7 primer. For transient expression, cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium (Gibco-BRL) containing 5% fetal bovine serum (Gibco-BRL), 5% supplemented calf serum (Hyclone Laboratories), and 2 mM
glutamine. Cells were transfected with expression plasmids by use of Lipofectamine 2000 reagent (Invitrogen). At 18–24 h after
transfection, COS-7 cells grown on glass cover slips were ﬁxed in 3.5% paraformaldehyde, permeabilized in 0.2% Triton X-100, and
immunostained with rabbit FLAG antibody (Sigma) followed by Alexa Fluor 488 goat anti-rabbit IgG (Molecular Probes). Cell nuclei were
counterstained (blue) with DAPI (4′,6-Diamidino-2-phenylindole [Molecular Probes]). E, Immunoblot analysis of VLPs produced by HEK
293T cells cotransfected with plasmids encoding Gag (p24 antibody) and CHMP4B1–150 (FLAG antibody). Top blot shows Gag recovered
in VLPs, and middle blot shows Gag in cell lysates. Bottom blot shows that the levels of CHMP4B1–150 were similar in cell lysates;
however, the D129V substitution increased the electrophoretic mobility of the mutant fragment on SDS (sodium dodecyl sulfate)
polyacrylamide gels compared with its wild-type counterpart. For VLPs, HEK 293T cells were transfected with 4 mg pCMV55 encoding
HIV Gag, alone or together with 1mg of the indicated CHMP4B construct. At 18–24 h after transfection, media containing VLPs was
harvested and clariﬁed by passing through a 0.45 mm ﬁlter. VLPs were pelleted by centrifugation (3 h) through a 20% sucrose cushion
at 26,000 rpm in SW41 Ti rotor (Beckman Coulter). VLPs and cell lysates were resuspended in sodium dodecyl sulfate (SDS) sample
buffer, were separated by SDS-polyacrylamide gel electrophoresis, and then were analyzed by immunoblotting using rabbit antibody
against p24, the capsid domain of HIV Gag, horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG, and the SuperSignal West
Pico chemiluminescence detection kit (Pierce). Immunoblot signals were quantiﬁed using the Odyssey Infrared Imaging System (Li-Cor
Bioscience).
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